Trial Profile
An Open-Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 26 Sep 2023
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary) ; Rebastinib (Primary)
- Indications Advanced breast cancer; Carcinoma; Endometrial cancer; Gynaecological cancer; Inflammatory breast cancer; Ovarian cancer; Sarcoma; Solid tumours; Triple negative breast cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Deciphera Pharmaceuticals
- 18 Sep 2023 Status changed from active, no longer recruiting to completed.
- 29 Sep 2021 Status changed from recruiting to active, no longer recruiting.
- 21 Sep 2021 Results (as of 19 March 2021; n=38) presented at the 46th European Society for Medical Oncology Congress.